Prospera Financial Services Inc Has $937,000 Stake in Gilead Sciences Inc. (GILD)
Prospera Financial Services Inc raised its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 23.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,235 shares of the biopharmaceutical company’s stock after buying an additional 2,138 shares during the period. Prospera Financial Services Inc’s holdings in Gilead Sciences were worth $937,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. WealthTrust Axiom LLC raised its stake in Gilead Sciences by 3.9% in the second quarter. WealthTrust Axiom LLC now owns 8,612 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 320 shares during the last quarter. Narwhal Capital Management raised its stake in Gilead Sciences by 11.9% in the second quarter. Narwhal Capital Management now owns 26,820 shares of the biopharmaceutical company’s stock worth $2,237,000 after buying an additional 2,855 shares during the last quarter. PGGM Investments raised its stake in Gilead Sciences by 19.8% in the second quarter. PGGM Investments now owns 1,301,945 shares of the biopharmaceutical company’s stock worth $108,608,000 after buying an additional 215,288 shares during the last quarter. HL Financial Services LLC raised its stake in Gilead Sciences by 13.9% in the second quarter. HL Financial Services LLC now owns 76,018 shares of the biopharmaceutical company’s stock worth $6,341,000 after buying an additional 9,292 shares during the last quarter. Finally, Orca Investment Management LLC purchased a new stake in Gilead Sciences during the second quarter worth $1,029,000. 77.94% of the stock is owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.27% during trading on Friday, hitting $75.24. 11,149,150 shares of the stock traded hands. Gilead Sciences Inc. has a 1-year low of $74.92 and a 1-year high of $111.11. The company has a market cap of $99.29 billion, a PE ratio of 6.60 and a beta of 1.10. The company has a 50 day moving average of $78.95 and a 200-day moving average of $85.05.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter in the previous year, the company earned $3.15 EPS. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
GILD has been the subject of a number of recent analyst reports. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 price target for the company. in a report on Wednesday, July 6th. Leerink Swann reaffirmed a “buy” rating and set a $120.00 price target (down from $123.00) on shares of Gilead Sciences in a report on Thursday, June 9th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $120.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a report on Monday, July 11th. Finally, RBC Capital Markets set a $105.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, August 11th. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $104.71.
In related news, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the transaction, the insider now owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the transaction, the executive vice president now owns 64,122 shares in the company, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.